DentalPlans.com >
Dental Health Articles >
HealthnewsDigest.com
>
Non Invasive Treatment for
Non-Invasive Treatment for Depression Made Available for Patients
|
 |
| |
|
|
Updated: 10/9/2008 4:00:36 PM |
|
|
(HealthNewsDigest.com) - CHICAGO – Transcranial Magnetic Stimulation (TMS) therapy has received clearance from the U.S. Food and Drug Administration (FDA) and is now an entirely new treatment option for patients suffering from depression.
Dr. Phil Janicak, a professor of psychiatry at Rush University Medical Center, was the principal investigator for the clinical trials of TMS, which is a system that uses repeated short bursts of magnetic energy introduced through the scalp to stimulate nerve cells in the brain to alleviate major depression.
TMS therapy, which is developed by Neuronetics, Inc., is an effective, non-drug treatment of Major Depressive Disorder in adult patients who have failed to achieve satisfactory improvement from antidepressant medication.
“In the randomized, controlled trial conducted for FDA clearance, TMS Therapy demonstrated statistically and clinically significant treatment effects,” said Dr. Janicak. “It’s particularly noteworthy that these outcomes were achieved without systemic side effects, such as weight gain and sexual dysfunction.”
TMS therapy was evaluated for efficacy, safety and tolerability in the acute treatment of major depression in patients who had failed to receive benefit from prior antidepressant medications. Throughout the study, more than 10,000 active TMS treatment sessions were safely performed. There were no systemic side effects such as weight gain, sexual dysfunction, sedation, nausea or dry mouth. There were no adverse memory effects, seizures or device-drug interactions. Overall, less than five percent of patients discontinued the study due to adverse events. Also, during the six-month follow-up period, there were no new safety issues compared with those seen during the acute treatment phase.
Patients treated with TMS therapy do not require anesthesia or sedation and remain awake and alert. It is a 40-minute outpatient procedure that is prescribed by a psychiatrist and performed in an outpatient setting. The treatment is typically administered daily for four-to-six-weeks.
Depression affects at least 14 million American adults each year. Researchers estimate that by the year 2020, depression will be the second leading cause of disability worldwide. About two-thirds of those who experience an episode of depression will have at least one other episode in their lives. Depression is a debilitating illness, and existing treatment options are frequently ineffective or intolerable due to side effects. Current antidepressant therapies are not beneficial for at least a third of depressed individuals, leaving many with a lack of adequate treatment options.
“Before now, few options have been available for them other than complex and often unproven combinations of medications,” said Dr. Janicak. “Now, with the FDA clearance of NeuroStar TMS Therapy, there is new hope."
www.HealthNewsDigest.com
Read Original Article
© 2008 HealthnewsDigest.com
|
Enter your ZIP code to compare the savings and benefits offered by the discount dental plans in your area. Take the first step toward a healthier smile and start saving today!
|
|
|
 |
|
|
|
|
 |
|
|
|
The DENTALPLANS.COM website is administered by
DENTALPLANS.COM, INC., a licensed Florida Discount Medical Plan Organization,
8100 S.W. 10th Street Suite #2000, Plantation, FL 33324. Plans and Programs offered by
DentalPlans.com are not health insurance policies. Plans and Programs offered
by DentalPlans.com provide discounts at certain health care providers for
medical services. Plans and Programs offered by DentalPlans.com do not make
payments directly to the providers of medical services. The Plan or Program
member is obligated to pay for all health care services but will receive a
discount from those health care providers who have contracted with the Plan,
Program or discount plan organization.
© 1999-2008 DentalPlans.com, Inc. All Rights
Reserved. Patents Pending.
|
|
|